{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:38:00Z","timestamp":1792521480098,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Locally advanced prostate cancer (PCa) encompasses a heterogeneous group of patients, including those with clinical stage T3\u2013T4 disease and\/or regional lymph node involvement (cN1), without distant metastases. While curative-intent treatment remains the goal in many cases, optimal management strategies are still subject to debate due to limited high-level evidence and variability in clinical guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This narrative review summarizes current treatment guidelines, appraises recent clinical evidence, and offers an expert perspective on contemporary management strategies for patients with locally advanced PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of international guidelines and recent clinical trials was conducted, focusing on the role of external beam radiotherapy (EBRT), androgen deprivation therapy (ADT), radical prostatectomy (RP), and systemic treatment intensification using androgen receptor pathway inhibitors (ARPIs) and chemotherapy. In addition, we highlight the impact of novel imaging modalities such as PSMA-PET\/CT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The established standard of care remains EBRT combined with ADT, with the addition of abiraterone now recommended for selected high-risk cases. RP, although not yet supported by randomized trials, may provide oncological and functional benefits in carefully chosen patients and is increasingly being incorporated into multimodal treatment strategies. The role of intensified neoadjuvant or adjuvant systemic therapies, however, remains under investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current management of locally advanced PCa requires individualized decision-making based on modern imaging modalities, patient characteristics, tumor biology, and available resources. While EBRT based multimodal concepts are mainly the preferred treatment, RP based multimodal concepts play an important role in selected cases. Emerging systemic therapies and advanced imaging may further refine treatment strategies in the near future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06190-x","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:42:43Z","timestamp":1769125363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Contemporary management of locally advanced prostate cancer: a narrative review and expert perspective"],"prefix":"10.1007","volume":"44","author":[{"given":"Mona","family":"Kafka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"6190_CR1","unstructured":"2021_QK_Prostatakarzinom_C_Schneider.pdf [Internet]. [zitiert 13. August 2025]. Verf\u00fcgbar unter: https:\/\/kkrbb.de\/wp-content\/uploads\/2022\/04\/2021_QK_Prostatakarzinom_C_Schneider.pdf"},{"issue":"2","key":"6190_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 86(2):148\u2013163","journal-title":"Eur Urol August"},{"key":"6190_CR3","unstructured":"Langer T S3\u2013Leitlinie Prostatakarzinom. Leitlinienprogramm Onkologie \u2013 Deutsche Krebsgesellschaft e. V., Deutsche Krebshilfe, AWMF. Empfehlungen zur Diagnostik und Therapie des lokal fortgeschrittenen Prostatakarzinoms. 2025;(Version 8.0)"},{"issue":"3","key":"6190_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.urology.2007.11.020","volume":"72","author":"DJ Kaplan","year":"2008","unstructured":"Kaplan DJ, Crispen PL, Greenberg RE, Chen DYT, Viterbo R, Buyyounouski MK (2008) Residual prostate cancer following radiotherapy: a study of radical cystoprostatectomy specimens. Urology. 72(3):654\u2013658","journal-title":"Urology"},{"issue":"10323","key":"6190_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 399(10323):447\u2013460","journal-title":"Lancet"},{"issue":"3","key":"6190_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B (2024) NCCN guidelines\u00ae insights: prostate cancer, version 3.2024. J Natl Compr Cancer Netw JNCCN. 22(3):140\u2013150","journal-title":"J Natl Compr Cancer Netw JNCCN April"},{"issue":"1","key":"6190_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 208(1):10\u201318","journal-title":"J Urol Juli"},{"issue":"1","key":"6190_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up. J Urol Juli 208(1):19\u201325","journal-title":"J Urol Juli"},{"issue":"1","key":"6190_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/JU.0000000000002759","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions. J Urol. 208(1):26\u201333","journal-title":"J Urol"},{"issue":"9660","key":"6190_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","volume":"373","author":"A Widmark","year":"2009","unstructured":"Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial. Lancet Lond Engl. 373(9660):301\u2013308","journal-title":"Lancet Lond Engl 24 Januar"},{"issue":"11","key":"6190_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11(11):1066\u20131073","journal-title":"Lancet Oncol"},{"issue":"5","key":"6190_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","volume":"61","author":"MV Pilepich","year":"2005","unstructured":"Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85\u201331. Int J Radiat Oncol 1 April 61(5):1285\u20131290","journal-title":"Int J Radiat Oncol 1 April"},{"issue":"24","key":"6190_CR13","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh ACM, Oddens J, Poortmans PMP (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 11 Juni 360(24):2516\u20132527","journal-title":"N Engl J Med 11 Juni"},{"issue":"7","key":"6190_CR14","doi-asserted-by":"publisher","first-page":"djv119","DOI":"10.1093\/jnci\/djv119","volume":"107","author":"CC Lin","year":"2015","unstructured":"Lin CC, Gray PJ, Jemal A, Efstathiou JA (2015) Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst. 107(7):djv119","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6190_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.ijrobp.2018.04.023","volume":"101","author":"AK Bryant","year":"2018","unstructured":"Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ (2018) Definitive radiation therapy and survival in clinically node-positive prostate cancer. Int J Radiat Oncol Biol Phys. 101(5):1188\u20131193","journal-title":"Int J Radiat Oncol Biol Phys 1 August"},{"issue":"15","key":"6190_CR16","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.3390\/cancers13153868","volume":"13","author":"M Onishi","year":"2021","unstructured":"Onishi M, Kawamura H, Murata K, Inoue T, Murata H, Takakusagi Y (2021) Intensity-modulated radiation therapy with simultaneous integrated boost for clinically node-positive prostate cancer: a single-institutional retrospective study. Cancers. 13(15):3868","journal-title":"Cancers"},{"key":"6190_CR17","unstructured":"Aragon pharmaceuticals IATLAS, randomized A double-blind, Placebo-controlled phase 3 study of JNJ-56021927. In subjects with High-risk, localized or locally advanced prostate cancer receiving treatment with primary radiation therapy [Internet]. clinicaltrials.gov; 2025 [zitiert 13. August 2025]. Report No.: NCT02531516. Verf\u00fcgbar unter: https:\/\/clinicaltrials.gov\/study\/NCT02531516"},{"key":"6190_CR18","unstructured":"University of Sydney randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD [Internet]. clinicaltrials.gov; 2025 Mai [zitiert 13. August 2025]. Report No.: NCT02446444. Verf\u00fcgbar unter: https:\/\/clinicaltrials.gov\/study\/NCT02446444"},{"issue":"2","key":"6190_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 17(2):243\u2013256","journal-title":"Lancet Oncol"},{"key":"6190_CR20","doi-asserted-by":"publisher","first-page":"viii271","DOI":"10.1093\/annonc\/mdy284","volume":"29","author":"K Fizazi","year":"2018","unstructured":"Fizazi K, Carmel A, Joly F, Delva R, Gravis G, Rolland F (2018) Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. Ann Oncol. 29:viii271","journal-title":"Ann Oncol"},{"issue":"6suppl","key":"6190_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1200\/JCO.2020.38.6_suppl.333","volume":"38","author":"HM Sandler","year":"2020","unstructured":"Sandler HM, Karrison T, Sartor AO, Gomella LG, Amin MB, Purdy J (2020) Adjuvant docetaxel for high-risk localized prostate cancer: update of NRG Oncology\/RTOG 0521. J Clin Oncol. 38(6suppl):333\u2013333","journal-title":"J Clin Oncol"},{"issue":"4","key":"6190_CR22","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2007.03.056","volume":"52","author":"U Zwergel","year":"2007","unstructured":"Zwergel U, Suttmann H, Schroeder T, Siemer S, Wullich B, Kamradt J (2007) Outcome of prostate cancer patients with initial PSA\u2009>\u2009or =\u200920 ng\/ml undergoing radical prostatectomy. Eur Urol. 2(4):1058\u20131065","journal-title":"Eur Urol"},{"issue":"3","key":"6190_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.juro.2006.04.048","volume":"176","author":"JF Donohue","year":"2006","unstructured":"Donohue JF, Bianco FJ, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT (2006) Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 176(3):991\u2013995","journal-title":"J Urol"},{"issue":"6","key":"6190_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/cncr.22116","volume":"107","author":"PJ Bastian","year":"2006","unstructured":"Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL (2006) Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107(6):1265\u20131272","journal-title":"Cancer"},{"issue":"2","key":"6190_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","volume":"178","author":"O Yossepowitch","year":"2007","unstructured":"Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178(2):493\u2013499 Discussion 499","journal-title":"J Urol"},{"issue":"3","key":"6190_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4103\/1008-682X.160884","volume":"18","author":"K Chang","year":"2016","unstructured":"Chang K, Qin XJ, Zhang HL, Dai B, Zhu Y, Shi GH (2016) Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005. Asian J Androl 18(3):452\u2013455","journal-title":"Asian J Androl"},{"issue":"5","key":"6190_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","volume":"107","author":"J Walz","year":"2011","unstructured":"Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O (2011) Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int M\u00e4rz 107(5):765\u2013770","journal-title":"BJU Int M\u00e4rz"},{"issue":"1","key":"6190_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2010.03.001","volume":"58","author":"M Spahn","year":"2010","unstructured":"Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B (2010) Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng\/ml: a European multi-institutional study of 712 patients. Eur Urol 58(1):1\u20137 Discussion 10\u201311","journal-title":"Eur Urol Juli"},{"issue":"2","key":"6190_CR29","first-page":"92","volume":"32","author":"M Oderda","year":"2025","unstructured":"Oderda M, Calleris G, Iorio GC, Simone G, Gontero P (2025) Radical prostatectomy in multimodal setting: current role of neoadjuvant and adjuvant hormonal or chemotherapy-based treatments. Curr Oncol Tor Ont 7 Februar 32(2):92","journal-title":"Curr Oncol Tor Ont 7 Februar"},{"issue":"4","key":"6190_CR30","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0022-5347(01)61640-9","volume":"161","author":"R Ghavamian","year":"1999","unstructured":"Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H (1999) Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN\u2009+\u2009prostate cancer: a matched comparison. J Urol 161(4):1223\u20131227 Discussion 1227\u20131228","journal-title":"J Urol April"},{"issue":"6","key":"6190_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7(6):472\u2013479","journal-title":"Lancet Oncol"},{"issue":"7","key":"6190_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","volume":"35","author":"CC Parker","year":"2024","unstructured":"Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR (2024) Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol Off J Eur Soc Med Oncol 35(7):656\u2013666","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10","key":"6190_CR33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21(10):1331\u20131340","journal-title":"Lancet Oncol"},{"issue":"10","key":"6190_CR34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 21(10):1341\u20131352","journal-title":"Lancet Oncol"},{"issue":"10260","key":"6190_CR35","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P (2020) Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet Lond Engl 396(10260):1422\u20131431","journal-title":"Lancet Lond Engl"},{"issue":"20","key":"6190_CR36","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1200\/JCO.20.03714","volume":"39","author":"D Tilki","year":"2021","unstructured":"Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T (2021) Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol Off J Am Soc Clin Oncol 39(20):2284\u20132293","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"35","key":"6190_CR37","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","volume":"32","author":"F Abdollah","year":"2014","unstructured":"Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 32(35):3939\u20133947","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"6190_CR38","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00345-017-2079-4","volume":"35","author":"P Mandel","year":"2017","unstructured":"Mandel P, Rosenbaum C, Pompe RS, Steuber T, Salomon G, Chun FK (2017) Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. World J Urol 35(12):1833\u20131839","journal-title":"World J Urol"},{"issue":"26","key":"6190_CR39","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.20.00315","volume":"38","author":"JA Eastham","year":"2020","unstructured":"Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M (2020) cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 38(26):3042\u20133050","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"6190_CR40","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.clgc.2021.02.004","volume":"19","author":"C Chi","year":"2021","unstructured":"Chi C, Fan L, Dong B, Zhu Y, Xin Z, Pan J (2021) Efficacy of neoadjuvant chemohormonal therapy in oligometastatic hormone-sensitive prostate cancer: a prospective, three-arm, comparative propensity score match analysis. Clin Genitourin Cancer 19(4):e223\u2013e234","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"6190_CR41","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/JU.0000000000003876","volume":"211","author":"H Qian","year":"2024","unstructured":"Qian H, Chi C, Tricard T, Zhu Y, Dong L, Wang Y (2024) A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy. J Urol 211(5):648\u2013655","journal-title":"J Urol"},{"key":"6190_CR42","doi-asserted-by":"publisher","first-page":"1284899","DOI":"10.3389\/fphar.2023.1284899","volume":"14","author":"Y Wei","year":"2023","unstructured":"Wei Y, Zhang R, Zhong D, Chen Z, Chen G, Yang M (2023) Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer. Front Pharmacol 14:1284899","journal-title":"Front Pharmacol"},{"issue":"6","key":"6190_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","volume":"83","author":"G Devos","year":"2023","unstructured":"Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V (2023) ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for High-risk prostate cancer. Eur Urol 83(6):508\u2013518","journal-title":"Eur Urol Juni"},{"issue":"6","key":"6190_CR44","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","volume":"205","author":"RR McKay","year":"2021","unstructured":"McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ (2021) Outcomes of Post-Neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J Urol 205(6):1689\u20131697","journal-title":"J Urol"},{"issue":"4","key":"6190_CR45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41391-022-00496-8","volume":"25","author":"LS Lee","year":"2022","unstructured":"Lee LS, Sim AYL, Ong CW, Yang X, Ng CCY, Liu W (2022) NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis 25(4):741\u2013748","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"6190_CR46","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1200\/JCO.18.01777","volume":"37","author":"RR McKay","year":"2019","unstructured":"McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z (2019) Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol 37(11):923\u2013931","journal-title":"J Clin Oncol"},{"issue":"1","key":"6190_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JU.0000000000001702","volume":"206","author":"RR McKay","year":"2021","unstructured":"McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R (2021) Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. J Urol 206(1):80\u201387","journal-title":"J Urol Juli"},{"issue":"6","key":"6190_CR48","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.eururo.2018.01.012","volume":"73","author":"GM Ahlgren","year":"2018","unstructured":"Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A (2018) Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 Scandinavian prostate cancer group 12 trial. Eur Urol 73(6):870\u2013876","journal-title":"Eur Urol"},{"issue":"1","key":"6190_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","volume":"46","author":"F Ceci","year":"2019","unstructured":"Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F (2019) 68Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging 46(1):31\u201339","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"6190_CR50","doi-asserted-by":"publisher","first-page":"e046588","DOI":"10.1136\/bmjopen-2020-046588","volume":"11","author":"SJ Freedland","year":"2021","unstructured":"Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J (2021) A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open 11(8):e046588","journal-title":"BMJ Open"},{"issue":"10467","key":"6190_CR51","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P (2024) Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design. Lancet Lond Engl 404(10467):2065\u20132076","journal-title":"Lancet Lond Engl 23 November"},{"key":"6190_CR52","doi-asserted-by":"publisher","first-page":"1050317","DOI":"10.3389\/fonc.2022.1050317","volume":"12","author":"F Qi","year":"2022","unstructured":"Qi F, Xu W, Li L, Li X, Xu Z (2022) Evaluation of the role of local therapy in patients with cN1M0 prostate cancer: a population-based study from the SEER database. Front Oncol 12:1050317","journal-title":"Front Oncol"},{"issue":"3","key":"6190_CR53","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","volume":"73","author":"T Seisen","year":"2018","unstructured":"Seisen T, Vetterlein MW, Karabon P, Jindal T, Sood A, Nocera L (2018) Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph Node-positive disease at initial diagnosis. Eur Urol 73(3):452\u2013461","journal-title":"Eur Urol"},{"issue":"5\u20136","key":"6190_CR54","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/21681805.2018.1520295","volume":"52","author":"J Stranne","year":"2018","unstructured":"Stranne J, Brasso K, Brennhovd B, Johansson E, J\u00e4derling F, Kouri M (2018) SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand J Urol 52(5\u20136):313\u2013320","journal-title":"Scand J Urol"},{"issue":"4","key":"6190_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338\u2013351","journal-title":"N Engl J Med"},{"issue":"14","key":"6190_CR56","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1200\/JCO.18.02158","volume":"37","author":"SA Rosenthal","year":"2019","unstructured":"Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J (2019) Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial. J Clin Oncol Off J Am Soc Clin Oncol 37(14):1159\u20131168","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6190_CR57","unstructured":"GU Oncology Now [Internet] [August 2025]. Radiotherapy vs Radical Prostatectomy for High-Risk Prostate Cancer. Verf\u00fcgbar unter: https:\/\/www.guoncologynow.com\/post\/radiotherapy-results-in-lower-risk-of-distant-metastasis-in-high-risk-prostate-cancer-compared-with-radical-prostatectomy"},{"issue":"1","key":"6190_CR58","first-page":"2534579","volume":"38","author":"X Zhang","year":"2025","unstructured":"Zhang X, Pan S, Sun W, Wang C (2025) Survival benefit of radical prostatectomy in newly diagnosed metastatic prostate cancer varies by PSA level and site of metastasis. J Investig Surg Off J Acad Surg Res 38(1):2534579","journal-title":"J Investig Surg Off J Acad Surg Res"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06190-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06190-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06190-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:59:21Z","timestamp":1781629161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06190-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6190"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06190-x","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"122"}}